EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness

Xingnan Li, Paul Newbold, Rohit Katial, Ian Hirsch, Huashi Li, Ubaldo J Martin, Deborah A Meyers, Eugene R Bleecker

The Journal of Allergy and Clinical Immunology: In Practice · 2024

DOI: 10.1016/j.jaip.2024.04.026 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Xingnan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Arizona College of Medicine, Tucson, Ariz. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca PLC, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: An improved understanding of how severe asthma heterogeneity affects response could inform treatment decisions. OBJECTIVES: Characterize heterogeneity and benralizumab responsiveness in patients grouped by predefined Severe Asthma Research Program clusters using a multivariate approach. METHODS: In post-hoc analyses of the randomized, double-blind, placebo-controlled phase III SIROCCO (NCT01928771) and CALIMA (NCT01914757) studies, patients with severe asthma who received benralizumab or placebo were assigned to clusters using an established discriminant function to analyze 11 clinical characteristics simultaneously. The annualized asthma exacerbation rate, exacerbation incidence, and lung function were analyzed across clusters. RESULTS: Patients (n = 2,281) met criteria for four of five clusters: cluster 2 (early-onset moderate asthma, n = 393), cluster 4 (early-onset severe asthma, n = 386), cluster 3 (late-onset severe asthma, n = 641), and cluster 5 (late-onset severe, obstructed asthma, n = 861); no patients met cluster 1 criteria. Exacerbation rate reductions were significant in late-onset severe asthma (-48% [95% CI, -61% to -31%]; P < .0001) and late-onset severe, obstructed asthma (-50% [95% CI, -59% to -38%]; P < .0001), with nonsignificant reductions in early-onset clusters. These differences could not be fully explained by blood eosinophil count differences. Values for improvements in FEV1 were significant in late-onset severe asthma (+133 mL [95% CI, 66-200]; P = .0001) and late-onset severe, obstructed asthma (+160 mL [95% CI, 85-235]; P < .0001) while maintaining acute bronchodilator responsiveness. CONCLUSIONS: Benralizumab reduced exacerbations and improved lung function, primarily in late-onset asthma clusters. This multivariate approach to identify subphenotypes, potentially reflecting pathobiological mechanisms, can guide therapy beyond univariate approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedAdultCluster AnalysisDouble-Blind MethodTreatment OutcomeMultivariate AnalysisAgedSeverity of Illness IndexEosinophils

Stichwörter der Autor:innen

Antiasthmatic agentsAsthmaBenralizumabFEVHeterogeneityPhenotypic clusterRespiratory hypersensitivityVital capacity

Substanzen

benralizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Medicine, University of Arizona College of Medicine, Tucson, Ariz.
  • Late Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Md.
  • Division of Allergy and Clinical Immunology, National Jewish Health, Denver, Colo.
  • Department of Medicine, Mayo Clinic, Scottsdale, Ariz.
  • Department of Medicine, Mayo Clinic, Scottsdale, Ariz. Electronic address: Bleecker.Eugene@mayo.edu.

Förderung

  • AstraZeneca PLC
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Li, X., Newbold, P., Katial, R., Hirsch, I., Li, H., Martin, U. J., Meyers, D. A., & Bleecker, E. R. (2024). Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.04.026

Vancouver

Li X, Newbold P, Katial R, Hirsch I, Li H, Martin UJ, et al. Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2024.04.026

BibTeX
@article{Li2024,
  author = {Li, Xingnan and Newbold, Paul and Katial, Rohit and Hirsch, Ian and Li, Huashi and Martin, Ubaldo J and Meyers, Deborah A and Bleecker, Eugene R},
  title = {Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  doi = {10.1016/j.jaip.2024.04.026}
}
Kostenlos starten →